July 11, 2002 -- The U.S. Food and Drug Administration (FDA) has granted marketing approval to infliximab (Remicade) to provide long-term remission-level control of moderate to severe Crohn's disease.

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Expert Rev Clin Immunol. 2010;6(1):9-19. In a large study with a total of 165 consecutive patients who received 479 infliximab infusions, [111] the overall incidence of infusion reactions was ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Please provide your email address to receive an email when new articles are posted on . Patients with IBD who received rapid infusions of infliximab were not at elevated risk for infusion reaction ...

Sustained treatment with the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease reports a multi-center research team in the 4 May 2002, issue of ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

Infliximab is used to treat a variety of inflammatory disorders; however, infusion reactions can occur that might necessitate discontinuation of treatment. A study in Sweden has evaluated the ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohn’s disease, conclude authors of a study in this week’s issue of THE LANCET. Crohn’s disease is a ...

To evaluate the effect of infliximab over the initial 4 years of treatment on inflammatory ocular attacks and background retinal/disc vascular leakage in patients with refractory uveoretinitis ...